Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Brentuximab vedotin + nivolumab in lymphoma

David Straus • 18 Aug 2020
SOHO 2020
Hodgkin Lymphoma Lymphoma Antibodies Bleomycin Brentuximab vedotin Dacarbazine Doxorubicin Nivolumab Vinblastine

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses updates from a study evaluating brentuximab vedotin, an antibody-drug conjugate, in combination with nivolumab in relapsed/refractory Hodgkin lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Straus

6:38
IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus • 2 Dec 2020
8:50
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
David Straus • 2 Dec 2020
2:34
R/R lymphoma: checkpoint blockade and transplantation
David Straus • 18 Aug 2020
3:24
Treatment of bulky stage I/II lymphoma
David Straus • 18 Aug 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals